← All Newgenivf Group LTD filings

Newgenivf Group LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
NIVF
Newgenivf Group LTD
20-F: NewGenIVF Shifts to High-Risk Diversification Amid Core Business Decline
NewGenIVF Group Limited reported a net income driven by non-cash gains in 2025, despite a significant decline in its core fertility services revenue and a widening operating loss, as it aggressively diversifies into digital assets and real estate.
NASDAQ
NIVF
Newgenivf Group LTD
20-F/A: NewGenIvf Group Limited Files Amendment to 20-F, Reports Accumulated Deficit and Going Concern Uncertainty
NewGenIvf Group Limited files an amendment to its 2024 annual report, citing a going concern uncertainty and accumulated deficit, while also detailing various business activities including acquisitions, financing arrangements, and reverse merger discussions.
NASDAQ
NIVF
Newgenivf Group LTD
20-F: NewGenIvf Group Limited Files 20-F Annual Report, Cites Going Concern Uncertainty
NewGenIvf Group Limited's 20-F filing reveals a net loss for 2024 and concerns about its ability to continue as a going concern due to limited cash reserves.
NASDAQ
NIVF
Newgenivf Group LTD
20-F: NewGenIvf Group Adopts Code of Conduct and Files Annual Report on Form 20-F
NewGenIvf Group Limited files its annual report on Form 20-F, including a code of conduct emphasizing ethical and legal compliance.
NASDAQ
NIVF
Newgenivf Group LTD
20-F: NewGenIvf Group Limited Files 20-F Report Following Business Combination
NewGenIvf Group Limited files its 20-F report, detailing the completion of its business combination and providing information on its operations and financial condition.